ProCE Banner Activity

Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma

Slideset Download
Conference Coverage
Patients with BRAF-mutant melanoma who received treatment with MEDI4736 + trametinib + dabrafenib showed robust immune activation and promising objective response rate.

Released: June 03, 2015

Expiration: June 01, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation